CompletedNot Applicable

Hyperbaric Oxygen Therapy in Diabetic Foot

Mexico15 participantsStarted 2019-01-15

Plain-language summary

This study seeks to assess changes in genes that are related to inflammation and oxidative stress in patients with type 2 Diabetes with diabetic foot treated with hyperbaric chamber

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Men and women with diabetic foot and hyperbaric treatment. Ages 30-60 years. Signed informed consent form. Exclusion Criteria: * Patients with diabetic foot without presence of dermatologic lesions.

What they're measuring

Gene expression of superoxide dismutase 1/ SOD1

Timeframe: The effect of the hyperbaric chamber was evaluated after sessions 12 and 30, each session lasting 60 minutes for five consecutive days per week, for a total of 6 weeks.

Gene expression of superoxide dismutase 2

Timeframe: The effect of the hyperbaric chamber was evaluated after sessions 12 and 30, each session lasting 60 minutes for five consecutive days per week, for a total of 6 weeks.

Glutathione Peroxidase (GPX2)

Timeframe: The effect of the hyperbaric chamber was evaluated after sessions 12 and 30, each session lasting 60 minutes for five consecutive days per week, for a total of 6 weeks.

Interleukin-1β (IL-1β)

Timeframe: The effect of the hyperbaric chamber was evaluated after sessions 12 and 30, each session lasting 60 minutes for five consecutive days per week, for a total of 6 weeks.

Interleukin-4 (IL-4)

Timeframe: The effect of the hyperbaric chamber was evaluated after sessions 12 and 30, each session lasting 60 minutes for five consecutive days per week, for a total of 6 weeks.

Interleukin-12 (IL-12)

Timeframe: The effect of the hyperbaric chamber was evaluated after sessions 12 and 30, each session lasting 60 minutes for five consecutive days per week, for a total of 6 weeks.

Trial details

NCT IDNCT06502808

SponsorNational Polytechnic Institute, Mexico

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-01-15

View on ClinicalTrials.gov More Diabetic Foot Ulcer Neuropathic trials

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Gene expression of superoxide dismutase 1/ SOD1

Timeframe: The effect of the hyperbaric chamber was evaluated after sessions 12 and 30, each session lasting 60 minutes for five consecutive days per week, for a total of 6 weeks.

Gene expression of superoxide dismutase 2

Timeframe: The effect of the hyperbaric chamber was evaluated after sessions 12 and 30, each session lasting 60 minutes for five consecutive days per week, for a total of 6 weeks.

Glutathione Peroxidase (GPX2)

Timeframe: The effect of the hyperbaric chamber was evaluated after sessions 12 and 30, each session lasting 60 minutes for five consecutive days per week, for a total of 6 weeks.

Interleukin-1β (IL-1β)

Timeframe: The effect of the hyperbaric chamber was evaluated after sessions 12 and 30, each session lasting 60 minutes for five consecutive days per week, for a total of 6 weeks.

Interleukin-4 (IL-4)

Timeframe: The effect of the hyperbaric chamber was evaluated after sessions 12 and 30, each session lasting 60 minutes for five consecutive days per week, for a total of 6 weeks.

Interleukin-12 (IL-12)

Timeframe: The effect of the hyperbaric chamber was evaluated after sessions 12 and 30, each session lasting 60 minutes for five consecutive days per week, for a total of 6 weeks.